{"title":"通过靶向血管内皮生长因子通路，内司他丁延迟治疗对肺动脉高压具有保护作用。","authors":"Shuai Huang, Nannan Li, Dong Yan","doi":"10.23736/S0026-4806.21.07145-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Endostatin (ES) is an endogenous angiogenesis inhibitor. It is confirmed that ES has antitumor effects and plays a crucial part in regulating vascular smooth cells' proliferation. However, ES's effect on pulmonary hypertension (PH) is unclear. The aim of this study was to determine the effect of ES on PH's pathogenesis.</p><p><strong>Methods: </strong>PH was induced by pneumonectomy plus monocrotaline (MCT) injection, as indicated with significantly increased pulmonary arterial pressure and vascular wall thickness.</p><p><strong>Results: </strong>Immunohistochemical analysis showed that under physiological conditions, ES localized in endothelial cells (ECs) and spread to the muscular vascular layers in PH rats. ES was transfected into the lungs of rats intratracheally 2 weeks after MCT injection. Consequently, ES not only reduced elevated VEGF's expression but also reversed pulmonary artery remodeling. Eventually, ES improved elevated right ventricular (RV) mean pressure and RV hypertrophy.</p><p><strong>Conclusions: </strong>The administration of ES may be a new treatment for PH and PA remodeling, associating with the downregulation of VEGF production.</p>","PeriodicalId":18671,"journal":{"name":"Minerva medica","volume":" ","pages":"13-21"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Delayed treatment with endostatin displays a protective role against pulmonary hypertension by targeting VEGF pathway.\",\"authors\":\"Shuai Huang, Nannan Li, Dong Yan\",\"doi\":\"10.23736/S0026-4806.21.07145-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Endostatin (ES) is an endogenous angiogenesis inhibitor. It is confirmed that ES has antitumor effects and plays a crucial part in regulating vascular smooth cells' proliferation. However, ES's effect on pulmonary hypertension (PH) is unclear. The aim of this study was to determine the effect of ES on PH's pathogenesis.</p><p><strong>Methods: </strong>PH was induced by pneumonectomy plus monocrotaline (MCT) injection, as indicated with significantly increased pulmonary arterial pressure and vascular wall thickness.</p><p><strong>Results: </strong>Immunohistochemical analysis showed that under physiological conditions, ES localized in endothelial cells (ECs) and spread to the muscular vascular layers in PH rats. ES was transfected into the lungs of rats intratracheally 2 weeks after MCT injection. Consequently, ES not only reduced elevated VEGF's expression but also reversed pulmonary artery remodeling. Eventually, ES improved elevated right ventricular (RV) mean pressure and RV hypertrophy.</p><p><strong>Conclusions: </strong>The administration of ES may be a new treatment for PH and PA remodeling, associating with the downregulation of VEGF production.</p>\",\"PeriodicalId\":18671,\"journal\":{\"name\":\"Minerva medica\",\"volume\":\" \",\"pages\":\"13-21\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva medica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.23736/S0026-4806.21.07145-7\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/4/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"0\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S0026-4806.21.07145-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/29 0:00:00","PubModel":"Epub","JCR":"0","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：内ostatin（ES）是一种内源性血管生成抑制剂。已证实 ES 具有抗肿瘤作用，并在调节血管平滑细胞增殖方面发挥重要作用。然而，ES对肺动脉高压（PH）的影响尚不明确。我们的目的是确定 ES 对 PH 发病机制的影响：方法：通过肺切除术加注射单克隆肾上腺素（MCT）诱发肺动脉高压，肺动脉压和血管壁厚度明显增加：免疫组化分析表明，在生理条件下，ES定位于PH大鼠的内皮细胞（EC），并扩散到肌肉血管层。在注射 MCT 2 周后，将 ES 经气管内转染至大鼠肺部。结果，ES 不仅降低了血管内皮生长因子的表达，还逆转了肺动脉重塑。最终，ES 改善了右心室（RV）平均压升高和 RV 肥厚：结论：服用 ES 可能是治疗 PH 和 PA 重塑的一种新方法，它与血管内皮生长因子分泌的下调有关。
Delayed treatment with endostatin displays a protective role against pulmonary hypertension by targeting VEGF pathway.
Background: Endostatin (ES) is an endogenous angiogenesis inhibitor. It is confirmed that ES has antitumor effects and plays a crucial part in regulating vascular smooth cells' proliferation. However, ES's effect on pulmonary hypertension (PH) is unclear. The aim of this study was to determine the effect of ES on PH's pathogenesis.
Methods: PH was induced by pneumonectomy plus monocrotaline (MCT) injection, as indicated with significantly increased pulmonary arterial pressure and vascular wall thickness.
Results: Immunohistochemical analysis showed that under physiological conditions, ES localized in endothelial cells (ECs) and spread to the muscular vascular layers in PH rats. ES was transfected into the lungs of rats intratracheally 2 weeks after MCT injection. Consequently, ES not only reduced elevated VEGF's expression but also reversed pulmonary artery remodeling. Eventually, ES improved elevated right ventricular (RV) mean pressure and RV hypertrophy.
Conclusions: The administration of ES may be a new treatment for PH and PA remodeling, associating with the downregulation of VEGF production.
期刊介绍：
Minerva Medica publishes scientific papers on internal medicine. Manuscripts may be submitted in the form of editorials, original articles, review articles, case reports, special articles, letters to the Editor and guidelines. The journal aims to provide its readers with papers of the highest quality and impact through a process of careful peer review and editorial work. Duties and responsibilities of all the subjects involved in the editorial process are summarized at Publication ethics.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
